498 related articles for article (PubMed ID: 38012210)
21. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma.
Liu Q; Li R; Wu H; Liang Z
BMC Cancer; 2023 Mar; 23(1):226. PubMed ID: 36894917
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
Front Oncol; 2022; 12():988680. PubMed ID: 36203428
[TBL] [Abstract][Full Text] [Related]
23. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
Wang X; Jing H; Li H
Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
[TBL] [Abstract][Full Text] [Related]
24. System Analysis Based on Pancreatic Cancer Progression Identifies BRINP2 as a Novel Prognostic Biomarker.
Kang Y; Xu X; Liu J
Crit Rev Eukaryot Gene Expr; 2023; 33(7):1-16. PubMed ID: 37602449
[TBL] [Abstract][Full Text] [Related]
25. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
26. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
27. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
28. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
30. A novel sphingolipid metabolism-related long noncoding RNA signature predicts the prognosis, immune landscape and therapeutic response in pancreatic adenocarcinoma.
He X; Xu Z; Ren R; Wan P; Zhang Y; Wang L; Han Y
Heliyon; 2024 Jan; 10(1):e23659. PubMed ID: 38173505
[TBL] [Abstract][Full Text] [Related]
31. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
34. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
35. Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer.
Wang H; Lv Z; Xia H; Tang R; Liu M; Wang J; Wang J
Heliyon; 2023 Dec; 9(12):e21153. PubMed ID: 38094043
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response.
Jiang Y; Ye Y; Huang Y; Wu Y; Wang G; Gui Z; Zhang M; Zhang M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15069-15083. PubMed ID: 37620430
[TBL] [Abstract][Full Text] [Related]
37. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer.
Yao HF; Xu DP; Zheng JH; Xu Y; Jia QY; Zhu YH; Yang J; He RZ; Ma D; Yang MW; Fu XL; Liu DJ; Huo YM; Yang JY; Zhang JF
Apoptosis; 2023 Aug; 28(7-8):1090-1112. PubMed ID: 37079192
[TBL] [Abstract][Full Text] [Related]
38. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
Wang C; Wang Z; Zhao Y; Jia R
BMC Gastroenterol; 2022 Nov; 22(1):495. PubMed ID: 36451085
[TBL] [Abstract][Full Text] [Related]
40. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
Zhang Z; Wang J; Han W; Zhao L
BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]